Novartis cancels Beigene partnership as cancer drug gains EU approval
BioPharma
Bristol Myers Roche Tecentriq Bristol Myers Squibb Opdivo Mark Lanasa Merck Co European Medicines Agency
Source: biopharmadive.com
📰 Mark Lanasa News
Page 2 - Mark Lanasa News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Mark Lanasa. Real-time updates on events, politics, business and more.
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA (tislelizumab)
19.09.2023 - BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced that it has entered into an agreement with Novartis to regain worldwide rights to develop, manufacture, and commercialize TEVIMBRA ... Seite 1
Source: wallstreet-online.de
BeiGene Strengthens Global Portfolio and Regains Full Rights from Novartis for Anti-PD-1 Antibody TEVIMBRA® (tislelizumab)
Regulatory marketing applications for U.S. and EU under review, with plans to expand TEVIMBRA commercial presence worldwide TEVIMBRA is the cornerstone of BeiGene’s solid tumor portfolio,...
Source: marketscreener.com
Novel Gastric Cancer Drug Under FDA Review Improves Survival
Tislelizumab was found to improve overall survival among patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
United States Mark Lanasa European Medicines Agency Drug Administration Cancers Symposium Gastric Cancer
Source: curetoday.com
Tislelizumab Demonstrates Superior Overall Survival Compared With Chemotherapy
Efficacy and safety data for BeiGene’s therapy shows positive results for individuals with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Tislelizumab Beigene Mark Lanasa National Reimbursement Drug List National Healthcare Security Administration European Medicines Agency Solid Tumors
Source: pharmacytimes.com
Tislelizumab Plus Chemotherapy Meets OS End Point in Advanced Gastric/GEJ Adenocarcinoma
The combination of tislelizumab plus chemotherapy elicited a statistically significant and clinically meaningful improvement in overall survival compared with chemotherapy plus placebo in patients with advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma.
Mark Lanasa Solid Tumors Cancers Symposium Arkenauh T Tislelizumab Plus Chemotherapy Patients With Advanced Unresectable Or Metastatic Gastric Gastroesophageal Junction Adenocarcinoma
Source: onclive.com
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment setting ... | April 20, 2023
United Kingdom Mark Lanasa Drug Administration China National Healthcare Security Administration National Reimbursement Drug List European Medicines Agency
Source: marketscreener.com
BeiGene Announces Positive Phase 3 Tislelizumab Trial in Advanced Gastric or Gastroesophageal Juncti
Superior overall survival for tislelizumab plus chemotherapy versus chemotherapy in first-line treatment settingBASEL, Switzerland & BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global biotechnology company, today announced the global RATIONALE 305 trial met its pr...
United Kingdom Mark Lanasa Kevin Mannix Exchange Commission National Reimbursement Drug List China National Healthcare Security Administration
Source: pharmiweb.com
BeiGene Presents New Research from Tislelizumab Global Development Program at 2023 ASCO Gastrointestinal Cancers Symposium
Oral presentation for RATIONALE 305 showed improved survival and manageable safety profile for tislelizumab and chemotherapy in gastric or gastroesophageal junction cancer with PD-L1 expression BeiGene
Source: finanznachrichten.de
BeiGene Announces Data Presentations at ESMO 2022 Including Late-Breaking Oral Presentation for Tislelizumab in First-Line Unresectable Hepatocellular Cancer
10.09.2022 - BeiGene (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, shared updates from its solid ... Seite 1
Source: wallstreet-online.de